Week in Review: China's Sanpower Pays $820 for Provenge, a Prostate Immunotherapy
January 14, 2017 at 12:58 PM EST
Sanpower Group, a China conglomerate, paid $820 million to acquire Dendreon, which makes Provenge, the world's first immunotherapy, from Valeant Pharma.
